#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)January 25, 2017

 

 #### Basel, Switzerland

 

 

Novartis announces the company’s fourth quarter and 2016 full year financial results.

 

 

This morning, Novartis CEO Joe Jimenez announced fourth quarter and full year 2016 results. In his remarks Jimenez said: “Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround. Cosentyx reached blockbuster status in 2016, and the conditions are now in place for Entresto sales to accelerate in 2017. We made major strides in advancing our pipeline, executing our bolt-on M&A strategy and implementing our new focused organization. Today we are proposing an increase in our dividend and initiating a share buyback of up to USD 5 billion. Additionally, we are reviewing options for the Alcon Division to maximize shareholder value.”

## $2016 At A Glance

 ![2016 At A Glance](/sites/novartis_com/files/styles/crop_freeform/public/2021-07/financial-results-performance-highlights-2016-image.jpg.webp?itok=bMCbRbLi "2016 At A Glance")

 

---

## Annual Report 2016

The Novartis Annual Report 2016 reviews the company’s strategy and annual performance.

Visit the [Annual Report](/investors/reporting-and-transparency-hub "Reporting and transparency hub")



## Form 20-F 2016

Documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).

[English (PDF 3 MB)](/sites/novartis_com/files/novartis-20-f-2016.pdf "novartis-20-f-2016.pdf")









 



 [ 

 

###  Novartis Pipeline 

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines.

 

 

 ](https://www.novartis.com/research-development/novartis-pipeline) [ 

 

###  Novartis Corporate Fact Sheet 

The corporate fact sheet provides a comprehensive overview of Novartis overall as well as our divisions (Pharmaceuticals, Alcon, Sandoz), our research (NIBR) and development (Global Drug Development) organizations, and outlines our commitment to associates as well as Corporate Citizenship.

 

 

 ](/about) 





 

 [Download the complete Novartis Pipeline as of December 31, 2016 (PDF 92 KB)](/sites/novartis_com/files/novartis-pipeline-2016-annual-report.pdf "Download the complete Novartis Pipeline as of December 31, 2016 (PDF 92 KB)")